The Role of Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma - Neeraj Agarwal, MD
June 9, 2019
Dr. Neeraj Agarwal, MD, Profesor of medicine, physician and investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, Director of the Genitourinary Oncology (GU) Program, the Center of Investigational Therapeutics (CIT), co-lead of the Experimental Therapeutic Program (one of the four cancer center support grant programs at the HCI), and he serves on the cabinet of the Director of HCI.
Petros Grivas, M.D., Ph.D. is a board-certified oncologist at SCCA, director of UW Medicine's Genitourinary Cancers Program and a UW associate professor of Oncology. Dr. Grivas is considered and international expert in genitourinary cancer. He is dedicated to efficient, personalized, outstanding patient care and optimal patient-physician relationships. Dr. Grivas earned his M.D. and Ph.D. at the University of Patras in Greece. He is board certified in Oncology and Internal Medicine. He lectures internationally, pursues community outreach, leads studies and publishes novel research. He had a main role in clinical trials leading to FDA approval of new drugs for bladder and urothelial cancer.
CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial
Nephrectomy in the Era of Targeted Therapy: Takeaways from the CARMENA Trial
NCT00930033: Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib